Myriad Genetics Announces Research Collaboration to use Minimal Residual Disease Testing Platform
SALT LAKE CITY, June 12, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced an agreement with The University of Texas MD Anderson Cancer Center to support…